| Hans-Günter Meyer-Thompson | Verschiedene
USA. Reclassification Recommendations for Drug in ‘Magic Mushrooms’
USA. Reclassification Recommendations for Drug in ‘Magic Mushrooms’
If phase III clinical trials are successful, researchers suggest categorizing the drug as schedule IV. (John Hopkins, Medicine, Newsroom, 26.09.2018)